EMMANUELLE LAURENCE WAUBANT
Affiliation: University of California
- Environmental and genetic factors in pediatric inflammatory demyelinating diseasesEmmanuelle Waubant
From the Pediatric MS Center E W, UCSF Benioff Children s Hospital Neurology Department E W, UCSF, San Francisco, CA Murdoch Children s Research Institute A L P, Royal Children s Hospital, University of Melbourne, Australia Department of Biomedical and Specialty Surgical Sciences M P, University of Ferrara, Italy Neurosciences and Mental Health H H, The Hospital for Sick Children, Toronto, Canada Department of Neurology E M M, Johns Hopkins, Baltimore, MD and MS Center ErasMS, Department of Neurology R Q H, Erasmus MC, Rotterdam, The Netherlands
Neurology 87:S20-7. 2016....
- Switching multiple sclerosis patients with breakthrough disease to second-line therapyTamara Castillo-Trivino
Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA
PLoS ONE 6:e16664. 2011..The effect of natalizumab monotherapy in patients with breakthrough disease is unknown...
- Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosisEmmanuelle Waubant
Regional Pediatric Multiple Sclerosis Center, University of California San Francisco, San Francisco, CA 94158, USA
Mult Scler 19:891-5. 2013..Our aim was to determine if MS patients who were positive for these viruses had higher levels of antibodies to these viruses. We also assessed whether human leukocyte antigen (HLA)-DRB1*1501 genotype influenced viral antibody levels...
- Emerging therapies for MSE Waubant
UCSF MS Center, University of California San Francisco, 350 Parnassus Street, San Francisco, CA 94117, USA
Rev Neurol (Paris) 163:688-96. 2007..Finally, new therapeutic approaches are now also addressing neuroprotection and CNS repair...
- Spotlight on anti-CD20E Waubant
UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, California 94117, USA
Int MS J 15:19-25. 2008..This review will present the rational for B-cell based therapies in MS and related diseases and preliminary data suggesting a therapeutic benefit in MS and related diseases. In addition, other therapies aiming at CD20 will be reviewed...
- Pediatric multiple sclerosisEmmanuelle Waubant
Emmanuelle Waubant, MD, PhD University of California San Francisco, Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
Curr Treat Options Neurol 11:203-10. 2009..Recent data suggest that some children experience a disease breakthrough on first-line therapies approved for adult MS, and thus second-line therapies must be considered...
- Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adultsEmmanuelle Waubant
UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Ste 908, San Francisco, CA 94117, USA
Arch Neurol 66:967-71. 2009..To compare initial brain magnetic resonance imaging (MRI) characteristics of children and adults at multiple sclerosis (MS) onset...
- Common viruses associated with lower pediatric multiple sclerosis riskE Waubant
UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
Neurology 76:1989-95. 2011..We studied seroprevalence for Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) type 1 and HLA-DRB1*1501/1503 status as predictors of pediatric MS...
- Predictors of the location of multiple sclerosis relapseS Deen
Multiple Sclerosis Center, University of California at San Francisco, San Francisco, California 94117, USA
J Neurol Neurosurg Psychiatry 79:1190-3. 2008..This study sought to identify predictors of MS relapse location. Based on the current literature, two potential predictors were identified: treatment with interferon beta (IFNB) and location of previous relapse...
- Are initial demyelinating event recovery and time to second event under differential control?T West
University of California San Francisco Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
Neurology 67:809-13. 2006..The authors speculate that IDE recovery and time to second event are under separate biologic or genetic control, and as such, their clinical predictors are different...
- Quality of life in multiple sclerosis is associated with lesion burden and brain volume measuresE M Mowry
Department of Neurology, University of California, San Francisco, 94117, USA
Neurology 72:1760-5. 2009..Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is unclear whether HRQOL is associated with white matter lesion burden or measures of brain atrophy...
- Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndromeD T Okuda
Department of Neurology, University of California San Francisco, UCSF Multiple Sclerosis Center, San Francisco, CA 94117, USA
Neurology 72:800-5. 2009..Routinely encountered in clinical practice, the natural history or evolution of such individuals with respect to their risk of developing multiple sclerosis (MS) is unclear...
- The onset location of multiple sclerosis predicts the location of subsequent relapsesE M Mowry
Department of Neurology, University of California, Multiple Sclerosis Center, San Francisco, CA 94117, USA
J Neurol Neurosurg Psychiatry 80:400-3. 2009..We sought to determine if initial clinical demyelinating event (IDE) location predicts subsequent clinical relapse locations in early RRMS...
- Demyelinating events in early multiple sclerosis have inherent severity and recoveryE M Mowry
Department of Neurology, Multiple Sclerosis Center, University of California, San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
Neurology 72:602-8. 2009..We sought to identify the factors associated with relapse severity and recovery and to evaluate whether events have inherent severity or recovery...
- Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?D Chabas
UCSF Regional Pediatric Multiple Sclerosis Center, San Francisco, CA 94117, USA
Neurology 71:1090-3. 2008..Pediatric patients with MS may less often meet MRI diagnostic criteria for adults. Whether initial MRI presentation is distinct in prepubertal patients is unknown...
- Clinical characteristics of responders to interferon therapy for relapsing MSE Waubant
UCSF MS Center, San Francisco, CA 94117, USA
Neurology 61:184-9. 2003..To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders...
- IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMSE Waubant
UCSF Multiple Sclerosis Center, University of California, San Francisco 94117, USA
Neurology 60:52-7. 2003....
- An open label study of the effects of rituximab in neuromyelitis opticaB A C Cree
Multiple Sclerosis Center, University of California, San Francisco 94117, USA
Neurology 64:1270-2. 2005..Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013)...
- Younger children with MS have a distinct CSF inflammatory profile at disease onsetD Chabas
UCSF Regional Pediatric MS Center, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
Neurology 74:399-405. 2010..The clinical and MRI presentation differs between earlier- and later-onset pediatric multiple sclerosis (MS), whereas the effect of age on the CSF inflammatory profile is unknown and may contribute to delayed diagnosis...
- Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosisA Gajofatto
Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, California, USA
Mult Scler 15:50-8. 2009..Options for non-responders to relapsing-remitting multiple sclerosis (RRMS) first-line disease-modifying therapies (DMT) are limited. We explored whether switching first-line DMT is effective...
- Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measuresD T Okuda
UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA
Brain 132:250-9. 2009....
- IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosisE Waubant
UCSF Mt Zion Multiple Sclerosis Center, San Francisco, CA 94115, USA
J Interferon Cytokine Res 21:181-5. 2001..10, p = 0.047; Wilcoxon signed-rank test). These preliminary data suggest that IFN-beta1a therapy may increase TIMP-1 levels...
- Interferon beta-1a in children with multiple sclerosis is well toleratedE Waubant
UCSF Mt Zion Multiple Sclerosis Center, San Francisco, CA, USA
Neuropediatrics 32:211-3. 2001..Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults...
- Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MSE Waubant
UCSF Mt Zion Multiple Sclerosis Center, 1701 Divisadero Street, San Francisco, CA 94115, USA
J Neuroimmunol 112:139-45. 2001....
- Treatment of pediatric multiple sclerosis and variantsD Pohl
Department of Pediatrics and Pediatric Neurology, Georg August University Goettingen, Germany
Neurology 68:S54-65. 2007..Finally, an overview of symptomatic MS therapies and experiences with these treatments in pediatric patients is provided...
- Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline dataJ A Cohen
Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Mult Scler 14:370-82. 2008....
- Modafinil for fatigue in MS: a randomized placebo-controlled double-blind studyB Stankoff
Federation de Neurologie, Hopital de la Salpetriere, AP HP, Paris, France
Neurology 64:1139-43. 2005..To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)...
- Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MSD Brassat
Department of Neurology, Hopital Purpan, Toulouse University Medical Center, Toulouse, France
Neurology 59:954-5. 2002..Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone...